Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009:5:819-31.
doi: 10.2147/vhrm.s3430. Epub 2009 Oct 12.

Update on the clinical use of the low-molecular-weight heparin, parnaparin

Giuseppe Camporese  1 , Enrico Bernardi, Franco Noventa
Affiliations
Review

Update on the clinical use of the low-molecular-weight heparin, parnaparin

Giuseppe Camporese et al. Vasc Health Risk Manag. 2009.

Abstract

Parnaparin is a low-molecular-weight heparin that has widely shown its efficacy and safety in prevention of venous thromboembolism, in the treatment of chronic venous disorders, and in the treatment of venous and arterial (stable and unstable angina, acute ST-segment elevation myocardial infarction) thrombosis. Parnaparin at the respective dosages of 3200, 4250, 6400, or 12800 IUaXa for a period ranging from 3 to 5 days to 6 months, is usually administered subcutaneously by means of once-daily regimen and is better tolerated than unfractionated heparin at the injection site. In the variety of commercially available low-molecular-weight heparins, parnaparin represents a useful therapeutic option, even though little evidence is available comparing the superiority or the equivalent efficacy and safety of parnaparin to that of the unfractionated heparin or placebo. This review summarizes the available literature on the use of parnaparin in different settings of cardiovascular diseases, including papers published during the past year and ongoing studies.

Keywords: acute coronary syndromes; heparin; low-molecular-weight heparin; parnaparin; venous thromboembolism.

PubMed Disclaimer

References

    1. Alexander JH, Singh KP. Inhibition of factor Xa: a potential target for the development of new anticoagulants. Am J Cardiovasc Drugs. 2005;5(5):279–290. - PubMed
    1. Dettori AG. Parnaparin: a review of its pharmacological profile and clinical application. Drugs Today. 1995;31(1):19–35.
    1. Frampton JE, Faulds D. Parnaparin: a review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders. Drugs. 1994;47(4):652–676. - PubMed
    1. McKeage K, Keating GM. Parnaparin, A review of its use in the management of venous thromboembolism, chronic venous disease and other vascular disorders. Drugs. 2008;68(1):105–122. - PubMed
    1. Fluxum™ Summary of product characteristics. Bologna: Alfa Wassermann; 2007.

MeSH terms